Aroa Biosurgery (ASX: ARX) – soft-tissue regeneration

 

COMPANY SCOREBOARD

Pro PlusProCon PlusCon
  • Defensive revenue growth
  • Operational breakeven in FY25
  • Products pipeline
 
  • Lack retail investors on Hotcopper

ABOUT COMPANY

Aroa Biosurgery (ARX) (https://aroa.com/) is a soft-tissue regeneration company in NZ that develops, manufactures, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction

CAPITAL STRUCTURE

Several institutions have quietly built some stakes.

BUSINESS

Below is the company’s five years performance:

Tela Bio partnership makes half of the sales.

SUMMARY

The company will be a good defensive stock to hold if the market comes down in CY25. 50c W bottom seems solid.